New research suggests that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt conventional diet and exercise plans.
Findings released in a major health publication shows that while overweight people frequently drop about a fifth of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People buying such medications should be informed of the risk of rapid rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery suggests a return to pre-treatment weight in about 18 months.
Weighing Therapies
The analysis, which examined dozens of trials involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
Researchers point out that people who lose weight through diet and exercise typically experience a slower creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Nutrition scientists propose the mode of action of the injections explains the amplified regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations far above than normal may cause the system to produce less of its endogenous hormone, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making overeating a significant risk."
An Ongoing Issue?
The NHS recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, given the significant potential of relapse, the therapy should be considered life-long.
This view is echoed by drug manufacturers, who say that the findings "highlight the long-term character of obesity," similar to managing conditions like hypertension.
User Experiences
Users who have come off the jabs report a intense resurgence of hunger.
"I experienced a switch flipping and you become starving," recalled an individual.
The struggle is worsened if users have not adopted sustainable dietary or behavioural modifications during treatment.
Growing Interest
Figures show that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Use is higher among women compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic solution and maintained weight loss likely depends on integrated behavioural management.
